References of "Windecker, Stephan"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailTreatment of aortic stenosis with a self-expanding transcatheter valve: the International Multi-centre ADVANCE Study
Linke, Axel; Wenaweser, Peter; Gerckens, Ulrich et al

in European Heart Journal (2014)

Aim Transcatheter aortic valve implantation has become an alternative to surgery in higher risk patients with symptomatic aortic stenosis. The aim of the ADVANCE study was to evaluate outcomes following ... [more ▼]

Aim Transcatheter aortic valve implantation has become an alternative to surgery in higher risk patients with symptomatic aortic stenosis. The aim of the ADVANCE study was to evaluate outcomes following implantation of a self-expanding transcatheter aortic valve system in a fully monitored, multi-centre ‘real-world’ patient population in highly experienced centres. Methods and results Patients with severe aortic stenosis at a higher surgical risk inwhomimplantation of theCoreValve Systemwas decided by the Heart Teamwere included. Endpointswere a composite of major adverse cardiovascular and cerebrovascular events (MACCE; all-cause mortality, myocardial infarction, stroke, or reintervention) and mortality at 30 days and 1 year. Endpoint- related eventswere independently adjudicated based on Valve AcademicResearch Consortiumdefinitions.Atotal of 1015 patients [mean logistic EuroSCORE 19.4+12.3% [median (Q1,Q3), 16.0% (10.3, 25.3%)], age 81+6 years] were enrolled. Implantation of the CoreValve System led to a significant improvement in haemodynamics and an increase in the effective aortic valve orifice area. At 30 days, theMACCErate was 8.0% (95% CI: 6.3–9.7%), all-cause mortalitywas 4.5% (3.2–5.8%), cardiovascular mortality was 3.4% (2.3–4.6%), and the rate of stroke was 3.0% (2.0–4.1%). The lifethreatening or disabling bleeding rate was 4.0% (2.8–6.3%). The 12-month rates of MACCE, all-cause mortality, cardiovascular mortality, and stroke were 21.2% (18.4–24.1%), 17.9% (15.2–20.5%), 11.7% (9.4–14.1%), and 4.5% (2.9–6.1%), respectively. The 12-month rates of all-cause mortality were 11.1, 16.5, and 23.6% among patients with a logistic Euro- SCORE ≤10%, EuroSCORE 10–20%, and EuroSCORE .20% (P , 0.05), respectively. Conclusion The ADVANCE study demonstrates the safety and effectiveness of the CoreValve System with low mortality and stroke rates in higher risk real-world patients with severe aortic stenosis. [less ▲]

Detailed reference viewed: 6 (0 ULg)
Peer Reviewed
See detailLinee guida per il trattamento delle valvulopatie (versione 2012). Task Force congiunta per il Trattamento delle Valvulopatie della Societa Europea di Cardiologia (ESC) e dell'Associazione Europea di Chirurgia Cardiotoracica (EACTS).
Vahanian, Alec; Alfieri, Ottavio; Andreotti, Felicita et al

in Giornale Italiano di Cardiologia (2006) (2013), 14(3), 167-214

Detailed reference viewed: 7 (2 ULg)
Full Text
Peer Reviewed
See detailGrupo de Trabajo para el manejo del infarto agudo de miocardio con elevacion del segmento ST de la Sociedad Europea de Cardiologia (ESC).
Steg, Gabriel; James, Stefan K.; Atar, Dan et al

in Revista Espanola de Cardiologia (2013), 66(1), 531-5346

Detailed reference viewed: 18 (3 ULg)
Full Text
Peer Reviewed
See detail2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology.
Montalescot, Gilles; Sechtem, Udo; Achenbach, Stephan et al

in European heart journal (2013), 34(38), 2949-3003

Detailed reference viewed: 79 (0 ULg)
Full Text
Peer Reviewed
See detailActualizacion de las guias de la Sociedad Europea de Cardiologia (ESC) para el manejo de la fibrilacion auricular de 2010 Elaborada en colaboracion con la Asociacion Europea del Ritmo Cardiaco.
Camm, A. John; Lip, Gregory Y. H.; Caterina, Raffaele De et al

in Revista espanola de cardiologia (2013), 66(1), 541-5424

Detailed reference viewed: 5 (0 ULg)
Full Text
Peer Reviewed
See detailGuidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS).
Vahanian, Alec; Alfieri, Ottavio; Andreotti, Felicita et al

in European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery (2012), 42(4), 1-44

Detailed reference viewed: 24 (5 ULg)
Full Text
Peer Reviewed
See detailESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC).
Regitz-Zagrosek, Vera; Blomstrom Lundqvist, Carina; Borghi, Claudio et al

in European Heart Journal (2011), 32(24), 3147-97

Detailed reference viewed: 35 (2 ULg)
Full Text
Peer Reviewed
See detailESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).
Reiner, Zeljko; Catapano, Alberico L; De Backer, Guy et al

in European Heart Journal (2011), 32(14), 1769-818

Cardiovascular disease (CVD) due to atherosclerosis of the arterial vessel wall and to thrombosis is the foremost cause of premature mortality and of disability-adjusted life years (DALYs) in Europe, and ... [more ▼]

Cardiovascular disease (CVD) due to atherosclerosis of the arterial vessel wall and to thrombosis is the foremost cause of premature mortality and of disability-adjusted life years (DALYs) in Europe, and is also increasingly common in developing countries.1 In the European Union, the economic cost of CVD represents annually E192 billion1 in direct and indirect healthcare costs. The main clinical entities are coronary artery disease (CAD), ischaemic stroke, and peripheral arterial disease (PAD). The causes of these CVDs are multifactorial. Some of these factors relate to lifestyles, such as tobacco smoking, lack of physical activity, and dietary habits, and are thus modifiable. Other risk factors are also modifiable, such as elevated blood pressure, type 2 diabetes, and dyslipidaemias, or non-modifiable, such as age and male gender. These guidelines deal with the management of dyslipidaemias as an essential and integral part of CVD prevention. Prevention and treatment of dyslipidaemias should always be considered within the broader framework of CVD prevention, which is addressed in guidelines of the Joint European Societies' Task forces on CVD prevention in clinical practice.2 - 5 The latest version of these guidelines was published in 20075; an update will become available in 2012. These Joint ESC/European Atherosclerosis Society (EAS) guidelines on the management of dyslipidaemias are complementary to the guidelines on CVD prevention in clinical practice and address not only physicians [e.g. general practitioners (GPs) and cardiologists] interested in CVD prevention, but also specialists from lipid clinics or metabolic units who are dealing with dyslipidaemias that are more difficult to classify and treat. [less ▲]

Detailed reference viewed: 30 (0 ULg)